VIKING THERAPEUT.DL -,005 WKN: A12GD6 ISIN: US92686J1060 Kürzel: VKTX Forum: Aktien Thema: Hauptdiskussion

Was los heute ?? Kein Absturz ? 🤔😂😂

Rette sich, wer kann. Ein Absturz jagt den nächsten

Das ist total spannend jetzt. Ich glaube weiterhin an die Aktie und habe jetzt auch auf 727 Stück erhöht … das wird, auch wenn erst mittelfristig

Ich rate jedem hier, sich das transcript der Conference heute durchzulesen. Wenn ein Umsatz von 10 Mrd. $ realisiert werden kann (ohne Angabe eines Zeitrahmens), entspricht dies konservativ einem MC von 60 Mrd. $ und sogar 150 bis 200 Mrd. $, wenn der NVO-Multiplikator verwendet wird. Wenn der LLY-Multiplikator verwendet wird, sprechen wir näher an $400B.

Indirekt gesagt, dass es keinen Partner für Phase 3 gibt

And we will also, as I mentioned, that that maintenance study that we're looking at transitioning from high dose weekly to monthly injection. We'll also have oral cohorts in that study also to look at maintenance effects. A lot of discussion about supply chain and you know, API demands in peptide based drugs. So, we announced earlier this year a long term supply agreement with Cordon Pharma and this will guarantee us access to a multi ton annual supply of API, which expandable at our option. We have access to additional fill and finish capabilities of up to a hundred million annual units of vial and syringe product, well as 100,000,000 units of auto injector product. And also expandable at our option. Finally, we we also, in part of this agreement, we had have access to over a billion annual tablet capacity available to us. Economics, we will pay Corden hundred and 50,000,000 in milestone based payments from 2025 to 2028, and that's pretty evenly spread across those three years. Those payments are fully credited against future orders. So you know, you think of it as not really out of pocket, so to speak, since we get discounts on future orders.

Du aktuelle Studie läuft wohl nicht so gut hahaha: ,,keine Ahnung, was wir als Nächstes tun, wir müssen auf die Ergebnisse der Studie schauen“

So the takeaway here for us anyway, is that you really want start low and just go slow through the titration window. So the study takeaways for us after the thirteen week study, we saw up to 14.7% mean weight loss after thirteen weeks of weekly treatment. Really promising tolerability More than ninety percent of the treatment emergent adverse events were mild to moderate. The majority of the GI related adverse events occur early and then resolve with continued dosing. Really interesting durability of weight loss More than ninety percent of the efficacy retained four weeks after the last dose. And we think that that durability and PK profile would suggest that a monthly regimen is feasible.

Was bekommt man als Hartzer im Monat von den shorties, um täglich so einen Müll zu posten ? 20€ ? 50€ ?? 🤦🏻‍♂️🤦🏻‍♂️😂😂

😂😂😂😂😂 +2% …..lasst euch von diesem Typen hier nicht für dumm verkaufen. Langt wenn er es ist.

Wow, das Management ist so schlecht, verrückt Nur Verschiebungen

Aktuell von der Conference call !, Phase 3 later this month !! Absturz !!!! 😂😂😂😂

Und Absturz wieder. Was eine Drecksaktie.

👍

Jefferies Global Healthcare Conference Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference Dates: June 3-5, 2025 Presentation Timing: 11:40 a.m. – 12:10 p.m. Central on Thursday, June 5, 2025 Location: New York, NY; webcast available